Efficacy and safety of the BEBM (bendamustine, etoposide, busulfan, and melphalan) conditioning regimen for autologous stem-cell transplantation in non-Hodgkin lymphoma

International Journal of Hematology · Published 2026-08-05 · DOI 10.1007/s12185-026-04250-x

Authors (3)

Sang Hun Lee, Do Young Kim, Ho-Jin Shin

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Lee, S., Kim, D., Shin, H. (2026). Efficacy and safety of the BEBM (bendamustine, etoposide, busulfan, and melphalan) conditioning regimen for autologous stem-cell transplantation in non-Hodgkin lymphoma. International Journal of Hematology. https://doi.org/10.1007/s12185-026-04250-x

Related articles

• BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: comparative analysis of efficacy and toxicity · Annals of Hematology · 2008 · Cites or is cited by this article
• Recent advances in the pathophysiology and treatment of GVHD · International Journal of Hematology · 2026 · Same journal
• Immunological links between aplastic anemia and paroxysmal nocturnal hemoglobinuria · International Journal of Hematology · 2026 · Same journal
• Current status and challenges of TCR-T cell therapy for AML/MDS · International Journal of Hematology · 2026 · Same journal
• T-cell fitness, metabolic tumor volume, and serum LDH levels are associated with response to axicabtagene ciloleucel · International Journal of Hematology · 2026 · Same journal
• NPM1-rearranged AML: clinical features, molecular pathogenesis, and therapeutic perspectives · International Journal of Hematology · 2026 · Same journal
• Postmarketing surveillance study of asciminib in patients with resistant/intolerant chronic myeloid leukemia in Japan · International Journal of Hematology · 2026 · Same journal
• Genomic insights transform diagnosis, prognosis, and therapy in BCR::ABL1-negative myeloproliferative neoplasms · International Journal of Hematology · 2026 · Same journal
• Defibrotide for late-onset sinusoidal obstruction syndrome following umbilical cord blood transplantation: a single-center retrospective study · International Journal of Hematology · 2026 · Same journal
• Zanubrutinib for MYD88-negative Waldenström’s macroglobulinemia with massive splenomegaly · International Journal of Hematology · 2026 · Same journal